Amcal is reaching out to OTC codeine users in preparation for the looming upschedule
The Amcal banner is rolling out tailored pain management plans for patients in the lead-up to the 1 February 2018 upscheduling to prescription-only of medicines containing low-dose codeine.
Many pain sufferers are likely to be left wondering what options will be available to them, Amcal says.
Amcal Senior Pharmacist, James Nevile applauded pharmacists for their support and advice to patients seeking relief from pain, and their work with local GPs to find appropriate long term solutions.
He says that “Amcal is committed to supporting both pharmacies and patients as we move towards codeine becoming prescription only”.
“It’s so important that patients are supported during the transition and still have access to short term pain options in pharmacy after these changes take place,” he says.
“We’ve been working behind the scenes to make sure pharmacists are well-prepared with access to a huge range of resources including process and training guides, checklists to prepare for the changeover date, dialogue guides and FAQs.”
Part of the plan offer will include use of the database S.H.E.R.P.A. (Sigma Holistic Evidence References and Patient Advice) which Amcal hopes will help its members look into a personalised approach to pain management.
S.H.E.R.P.A. launched in March 2017.
“It will go a long way in assisting the personalised pain management plans for consumers and ensure they are receiving the best possible advice and treatment options,” Mr Nevile says.
“By preparing our pharmacists, we’re ensuring that customers will be supported through the change as much as possible.”